Put companies on watchlist
PolyPeptide Group
ISIN: CH1110760852
WKN: A3CNHV
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

PolyPeptide Group · ISIN: CH1110760852 · EQS - adhoc news (39 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1247643
10 November 2021 07:15AM

Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG


EQS Group-Ad-hoc: PolyPeptide Group / Key word(s): Transaction in Own Shares
Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG

10-Nov-2021 / 07:15 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Media Release

Ad hoc announcement pursuant to Art. 53 LR

Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG

Zug, 10 November 2021 - PolyPeptide Group AG ("PolyPeptide") has been informed that Draupnir Holding B.V. ("Draupnir"), which held 60.0% of PolyPeptide's share capital as of close of trading on SIX Swiss Exchange yesterday, placed a total of 1,500,000 existing ordinary shares in PolyPeptide (representing approx. 4.5% of PolyPeptide's share capital) through an accelerated bookbuilding offering to institutional investors overnight. Upon settlement of the placement, which is expected to occur on 12 November 2021 subject to customary closing conditions, Draupnir will hold approx. 55.5% of PolyPeptide's share capital. The free float in PolyPeptide shares, which according to SIX Swiss Exchange is presently 40.0%, will increase by approx. 4.5% to approx. 44.5%.

In the context of the placement, Draupnir has undertaken a lock-up commitment for a period of 130 days with respect to shares in PolyPeptide that will remain in its possession upon completion of the placement and PolyPeptide has been informed that Draupnir is committed to maintain a majority ownership in PolyPeptide for the foreseeable future.


Contact

PolyPeptide Group AG
Michael Stäheli
Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com
Tel. +41 41 723 20 34

About PolyPeptide

PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 1,000 employees, its diversity brings breadth, depth of knowledge and experience to the Group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide's shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, visit polypeptide.com.

PolyPeptide Group AG, Dammstrasse 19, CH-6300 Zug

Disclaimer

This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.

This document contains forward-looking statements including, but not limited to, statements regarding the completion of the transaction described herein, and Draupnir's investment in PolyPeptide Group AG. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results, performance or events to differ materially from the statements made herein.


Additional features:


File: Release Draupnir ABB_E

End of ad hoc announcement
Language: English
Company: PolyPeptide Group
Dammstrasse 19
CH-6300 Zug
Switzerland
Phone: +41 41 723 23 23
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 1247643

 
End of Announcement EQS Group News Service

1247643  10-Nov-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1247643&application_name=news&site_id=boersengefluester_html
Visual performance / price development - PolyPeptide Group
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.